Nordic Nanovector launches $63m primary block for clinical trials
Tonight, Nordic Nanovector, the Norwegian developer of radio-immunotherapeutics for haematological cancers, is raising Nkr527m ($63m) to finance clinical trials, by placing new shares with institutional investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: